Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Cythemias Cythemias for January/February 2020 BET inhibitor exhibits activity in myelofibrosis, Navitoclax may overcome ruxolitinib resistance in MF, More must reads Cythemias for March/April 2019 Back to the drawing board for MPN combo, More must reads
